Soleno Therapeutics Announces Appointment of Industry Veteran Gwen A. Melincoff to Board of Directors
April 29 2019 - 8:00AM
Soleno Therapeutics, Inc. (“Soleno”) (NASDAQ: SLNO), a
clinical-stage biopharmaceutical company developing novel
therapeutics for the treatment of rare diseases, today announced
the appointment of Gwen A. Melincoff, a biotechnology and
pharmaceutical industry veteran, to its Board of Directors,
effective April 26, 2019. Ms. Melincoff will replace Mahendra G.
Shah, Ph.D., who is stepping down from the Board.
“We are pleased to welcome Gwen as she brings a diverse and
extensive background spanning business development, capital
raising, research operations and marketing to our Board,” said
Anish Bhatnagar, M.D., Chief Executive Officer of Soleno. “With
experience serving on multiple public and private company boards,
we look forward to Gwen’s insightful and well-versed guidance with
our efforts to advance DCCR through our ongoing Phase 3 trial
toward commercialization. On behalf of the Board, I would also like
to sincerely thank Mahendra for his support and commitment to
Soleno since his tenure began in 2017 and wish him well in his next
endeavors.”
Ms. Melincoff said, “I am honored to join Soleno’s Board at such
an exciting time for the company and believe that DCCR has great
potential to be the first approved treatment for Prader-Willi
syndrome. I look forward to collaborating with the Soleno
team, providing guidance as the company progresses DCCR on the path
towards commercialization.”
Ms. Melincoff has over 25 years of leadership experience in the
biotechnology and pharmaceutical sector, and was named one of the
“Top Women in Biotech 2013” by FierceBiotech. She currently sits on
the board of directors of Photocure ASA, and Collegium
Pharmaceutical, and is an Advisor at Agent Capital, Phase 1
Ventures and Verge Genomics. She was previously a board member at
Kamada, as well as Tobira Therapeutics when Allergan acquired it
for $1.7 billion. She most recently served as Vice President of
Business Development at BTG International Inc and from 2004 to the
2013, was Senior Vice President of Business Development at Shire
Pharmaceuticals. She led Shire’s Strategic Investment Group (SIG)
and served as a board member/board observer at DBV Technologies, AM
Pharma, ArmaGen Technologies, Promethera Biosciences, Naurex Inc.
(acquired by Allergan), and Enterome. She was responsible for
the collaboration with New River Pharmaceuticals that led to the
$2.6 billion acquisition of the company. Prior to joining Shire,
Ms. Melincoff was Vice President of Business Development at Adolor
Corporation. Ms. Melincoff received her M.S. in Management from
Pennsylvania State University, completed her B.S. in Biology from
George Washington University, and attained the designation of
Certified Licensing Professional (CLP™).
About Soleno Therapeutics, Inc.Soleno is
focused on the development and commercialization of novel
therapeutics for the treatment of rare diseases. The company’s lead
candidate, DCCR, a once-daily oral tablet for the treatment of PWS,
is currently being evaluated in a Phase III clinical development
program.
For more information, please visit www.soleno.life.
Forward-Looking Statements This press release
contains forward-looking statements that are subject to many risks
and uncertainties. Forward-looking statements include statements
regarding our intentions, beliefs, projections, outlook, analyses
or current expectations concerning, among other things, our ability
to complete the Phase III clinical development program of DCCR in
PWS in 2019. We may use terms such as "believes," "estimates,"
"anticipates," "expects," "plans," "intends," "may," "could,"
"might," "will," "should," "approximately" or other words that
convey uncertainty of future events or outcomes to identify these
forward-looking statements. Although we believe that we have a
reasonable basis for each forward-looking statement contained
herein, we caution you that forward-looking statements are not
guarantees of future performance and that our actual results of
operations, financial condition and liquidity, and the development
of the industry in which we operate may differ materially from the
forward-looking statements contained in this presentation. As a
result of these factors, we cannot assure you that the
forward-looking statements in this press release will prove to be
accurate. Additional factors that could materially affect actual
results can be found in Soleno’s annual and quarterly reports filed
with the Securities and Exchange Commission, including under
the caption titled "Risk Factors." Soleno expressly disclaims any
intent or obligation to update these forward-looking statements,
except as required by law.
CONTACT:Brian RitchieLifeSci Advisors,
LLC212-915-2578
Soleno Therapeutics (NASDAQ:SLNO)
Historical Stock Chart
From Mar 2024 to Apr 2024
Soleno Therapeutics (NASDAQ:SLNO)
Historical Stock Chart
From Apr 2023 to Apr 2024